PE20181522A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer - Google Patents
Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancerInfo
- Publication number
- PE20181522A1 PE20181522A1 PE2018001012A PE2018001012A PE20181522A1 PE 20181522 A1 PE20181522 A1 PE 20181522A1 PE 2018001012 A PE2018001012 A PE 2018001012A PE 2018001012 A PE2018001012 A PE 2018001012A PE 20181522 A1 PE20181522 A1 PE 20181522A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- pyridazin
- cancer
- thadiazole
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101710184006 Glutaminase 1 Proteins 0.000 abstract 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- -1 6-fluoropyridazin -3-yl Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260784P | 2015-11-30 | 2015-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181522A1 true PE20181522A1 (es) | 2018-09-24 |
Family
ID=57460503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001012A PE20181522A1 (es) | 2015-11-30 | 2016-11-30 | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10040789B2 (OSRAM) |
| EP (1) | EP3383872B1 (OSRAM) |
| JP (1) | JP6821680B2 (OSRAM) |
| KR (1) | KR20180083411A (OSRAM) |
| CN (1) | CN108349965B (OSRAM) |
| AR (1) | AR106875A1 (OSRAM) |
| AU (1) | AU2016361834B2 (OSRAM) |
| BR (1) | BR112018008330B1 (OSRAM) |
| CA (1) | CA3005517C (OSRAM) |
| CL (1) | CL2018001409A1 (OSRAM) |
| CO (1) | CO2018006930A2 (OSRAM) |
| DK (1) | DK3383872T3 (OSRAM) |
| DO (1) | DOP2018000135A (OSRAM) |
| EA (1) | EA035519B9 (OSRAM) |
| ES (1) | ES2796562T3 (OSRAM) |
| IL (1) | IL259508A (OSRAM) |
| MX (1) | MX2018006483A (OSRAM) |
| MY (1) | MY195680A (OSRAM) |
| NI (1) | NI201800063A (OSRAM) |
| NZ (1) | NZ743699A (OSRAM) |
| PE (1) | PE20181522A1 (OSRAM) |
| PH (1) | PH12018501133A1 (OSRAM) |
| SG (1) | SG11201803808VA (OSRAM) |
| SV (1) | SV2018005700A (OSRAM) |
| TN (1) | TN2018000118A1 (OSRAM) |
| TW (1) | TW201731511A (OSRAM) |
| WO (1) | WO2017093301A1 (OSRAM) |
| ZA (1) | ZA201804361B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| JP7026852B2 (ja) * | 2018-10-16 | 2022-02-28 | メッドシャイン ディスカバリー インコーポレイテッド | チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用 |
| CN114560855B (zh) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 环烷基甲酰胺类衍生物、其制备方法及用途 |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CN105960405B (zh) | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 US US15/362,989 patent/US10040789B2/en active Active
- 2016-11-29 TW TW105139334A patent/TW201731511A/zh unknown
- 2016-11-30 MX MX2018006483A patent/MX2018006483A/es unknown
- 2016-11-30 ES ES16805078T patent/ES2796562T3/es active Active
- 2016-11-30 SG SG11201803808VA patent/SG11201803808VA/en unknown
- 2016-11-30 WO PCT/EP2016/079253 patent/WO2017093301A1/en not_active Ceased
- 2016-11-30 CA CA3005517A patent/CA3005517C/en active Active
- 2016-11-30 AR ARP160103664A patent/AR106875A1/es unknown
- 2016-11-30 NZ NZ743699A patent/NZ743699A/en unknown
- 2016-11-30 AU AU2016361834A patent/AU2016361834B2/en active Active
- 2016-11-30 EP EP16805078.9A patent/EP3383872B1/en active Active
- 2016-11-30 CN CN201680067210.XA patent/CN108349965B/zh active Active
- 2016-11-30 DK DK16805078.9T patent/DK3383872T3/da active
- 2016-11-30 BR BR112018008330-5A patent/BR112018008330B1/pt active IP Right Grant
- 2016-11-30 KR KR1020187017163A patent/KR20180083411A/ko not_active Withdrawn
- 2016-11-30 MY MYPI2018702070A patent/MY195680A/en unknown
- 2016-11-30 JP JP2018527201A patent/JP6821680B2/ja active Active
- 2016-11-30 TN TNP/2018/000118A patent/TN2018000118A1/en unknown
- 2016-11-30 EA EA201891239A patent/EA035519B9/ru not_active IP Right Cessation
- 2016-11-30 PE PE2018001012A patent/PE20181522A1/es unknown
-
2018
- 2018-05-22 IL IL259508A patent/IL259508A/en active IP Right Grant
- 2018-05-24 CL CL2018001409A patent/CL2018001409A1/es unknown
- 2018-05-29 SV SV2018005700A patent/SV2018005700A/es unknown
- 2018-05-29 DO DO2018000135A patent/DOP2018000135A/es unknown
- 2018-05-29 NI NI201800063A patent/NI201800063A/es unknown
- 2018-05-29 PH PH12018501133A patent/PH12018501133A1/en unknown
- 2018-06-28 ZA ZA2018/04361A patent/ZA201804361B/en unknown
- 2018-06-29 CO CONC2018/0006930A patent/CO2018006930A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181522A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| DOP2023000041A (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| CO2020016285A2 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| DOP2018000182A (es) | Benzamidas sustituidas con 1,3tiazol2ilo | |
| CL2016000866A1 (es) | Forma salina de hidrocloruro para la inhibición de ezh2 | |
| MX385731B (es) | Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| CO2022018715A2 (es) | Análogos de nucleósido de 1’-ciano y usos de los mismos | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| MX2020002825A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| MX383688B (es) | Derivados de piridona amida como agonistas de canales de sodio nav1. 8 y el uso de los mismos en el tratamiento de dolor. | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| PE20151072A1 (es) | Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| AR110249A1 (es) | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| CR10166A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| MX2018014232A (es) | Formulacion farmaceutica. | |
| BR112022005728A2 (pt) | Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas |